Modelling the value of innovative treatments for Alzheimer's disease in the United States
Alzheimer's disease (AD) is the predominant cause of dementia and a leading cause of death globally. With no cure or treatment to slow disease progression, AD-related healthcare costs are substantial and increase as the severity of the disease progresses. Given the complexity of this disease, i...
Gespeichert in:
| Veröffentlicht in: | Journal of medical economics 2021-01, Vol.24 (1), p.764-769 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 769 |
|---|---|
| container_issue | 1 |
| container_start_page | 764 |
| container_title | Journal of medical economics |
| container_volume | 24 |
| creator | Makin, Charles Neumann, Peter Peschin, Sue Goldman, Dana |
| description | Alzheimer's disease (AD) is the predominant cause of dementia and a leading cause of death globally. With no cure or treatment to slow disease progression, AD-related healthcare costs are substantial and increase as the severity of the disease progresses. Given the complexity of this disease, including initial pathophysiological damage occurring decades before clinical manifestation, finding new impactful treatments for AD relies on highly innovative research and development. However, such sizable and sustained investments bring into question whether conventional value assessment models are fit for this purpose. In this article, we examine the importance and challenges of assimilating the perspectives of varied stakeholders, including patients, caregivers, health systems, payers, and society at large, into a comprehensive value assessment model that may be well suited for a breakthrough treatment for AD. |
| doi_str_mv | 10.1080/13696998.2021.1927747 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_13696998_2021_1927747</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2528175535</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-cd12f02989e45be6fc883cb397e0f03d138d4419f512b23b323177416d8afb0e3</originalsourceid><addsrcrecordid>eNp9kE1v1DAQhi0EolXpTwD5BpcsHk-ysW9UVfmQinqglcrJcuIxNUriYnsXlV-Pl91yrC_jw_POx8PYaxArEEq8B1zrtdZqJYWEFWjZ923_jB2DbqFR2N8-r__KNDvoiJ3m_FPUhwiih5fsCFErLXR3zL5_jY6mKSw_eLkjvrXThnj0PCxL3NoStsRLIltmWkrmPiZ-Nv25ozBTepu5C5lspkr_S98soZDj34otlF-xF95OmU4P9YTdfLy4Pv_cXF59-nJ-dtmMLWBpRgfSC1n3obYbaO1HpXAcUPckvEAHqFzbgvYdyEHigBKhXgtrp6wfBOEJe7fve5_irw3lYuaQx3qTXShuspGdVNB3HXYV7fbomGLOiby5T2G26cGAMDux5lGs2Yk1B7E19-YwYjPM5P6nHjVW4MMeCEtVNNvfMU3OFPswxeSTXcaQDT494y-omYdW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2528175535</pqid></control><display><type>article</type><title>Modelling the value of innovative treatments for Alzheimer's disease in the United States</title><source>Taylor & Francis Open Access</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Makin, Charles ; Neumann, Peter ; Peschin, Sue ; Goldman, Dana</creator><creatorcontrib>Makin, Charles ; Neumann, Peter ; Peschin, Sue ; Goldman, Dana</creatorcontrib><description>Alzheimer's disease (AD) is the predominant cause of dementia and a leading cause of death globally. With no cure or treatment to slow disease progression, AD-related healthcare costs are substantial and increase as the severity of the disease progresses. Given the complexity of this disease, including initial pathophysiological damage occurring decades before clinical manifestation, finding new impactful treatments for AD relies on highly innovative research and development. However, such sizable and sustained investments bring into question whether conventional value assessment models are fit for this purpose. In this article, we examine the importance and challenges of assimilating the perspectives of varied stakeholders, including patients, caregivers, health systems, payers, and society at large, into a comprehensive value assessment model that may be well suited for a breakthrough treatment for AD.</description><identifier>ISSN: 1369-6998</identifier><identifier>EISSN: 1941-837X</identifier><identifier>DOI: 10.1080/13696998.2021.1927747</identifier><identifier>PMID: 33989095</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Alzheimer Disease - drug therapy ; Alzheimer's disease ; Caregivers ; Cost of Illness ; cost-effectiveness analysis ; drug therapy ; Health Care Costs ; healthcare costs ; Humans ; medical expenditure ; quality-adjusted life year ; United States</subject><ispartof>Journal of medical economics, 2021-01, Vol.24 (1), p.764-769</ispartof><rights>2021 Biogen. Published by Informa UK Limited, trading as Taylor & Francis Group. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-cd12f02989e45be6fc883cb397e0f03d138d4419f512b23b323177416d8afb0e3</citedby><cites>FETCH-LOGICAL-c413t-cd12f02989e45be6fc883cb397e0f03d138d4419f512b23b323177416d8afb0e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/13696998.2021.1927747$$EPDF$$P50$$Ginformaworld$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/13696998.2021.1927747$$EHTML$$P50$$Ginformaworld$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,27481,27903,27904,59119,59120</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33989095$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Makin, Charles</creatorcontrib><creatorcontrib>Neumann, Peter</creatorcontrib><creatorcontrib>Peschin, Sue</creatorcontrib><creatorcontrib>Goldman, Dana</creatorcontrib><title>Modelling the value of innovative treatments for Alzheimer's disease in the United States</title><title>Journal of medical economics</title><addtitle>J Med Econ</addtitle><description>Alzheimer's disease (AD) is the predominant cause of dementia and a leading cause of death globally. With no cure or treatment to slow disease progression, AD-related healthcare costs are substantial and increase as the severity of the disease progresses. Given the complexity of this disease, including initial pathophysiological damage occurring decades before clinical manifestation, finding new impactful treatments for AD relies on highly innovative research and development. However, such sizable and sustained investments bring into question whether conventional value assessment models are fit for this purpose. In this article, we examine the importance and challenges of assimilating the perspectives of varied stakeholders, including patients, caregivers, health systems, payers, and society at large, into a comprehensive value assessment model that may be well suited for a breakthrough treatment for AD.</description><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer's disease</subject><subject>Caregivers</subject><subject>Cost of Illness</subject><subject>cost-effectiveness analysis</subject><subject>drug therapy</subject><subject>Health Care Costs</subject><subject>healthcare costs</subject><subject>Humans</subject><subject>medical expenditure</subject><subject>quality-adjusted life year</subject><subject>United States</subject><issn>1369-6998</issn><issn>1941-837X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><recordid>eNp9kE1v1DAQhi0EolXpTwD5BpcsHk-ysW9UVfmQinqglcrJcuIxNUriYnsXlV-Pl91yrC_jw_POx8PYaxArEEq8B1zrtdZqJYWEFWjZ923_jB2DbqFR2N8-r__KNDvoiJ3m_FPUhwiih5fsCFErLXR3zL5_jY6mKSw_eLkjvrXThnj0PCxL3NoStsRLIltmWkrmPiZ-Nv25ozBTepu5C5lspkr_S98soZDj34otlF-xF95OmU4P9YTdfLy4Pv_cXF59-nJ-dtmMLWBpRgfSC1n3obYbaO1HpXAcUPckvEAHqFzbgvYdyEHigBKhXgtrp6wfBOEJe7fve5_irw3lYuaQx3qTXShuspGdVNB3HXYV7fbomGLOiby5T2G26cGAMDux5lGs2Yk1B7E19-YwYjPM5P6nHjVW4MMeCEtVNNvfMU3OFPswxeSTXcaQDT494y-omYdW</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Makin, Charles</creator><creator>Neumann, Peter</creator><creator>Peschin, Sue</creator><creator>Goldman, Dana</creator><general>Taylor & Francis</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20210101</creationdate><title>Modelling the value of innovative treatments for Alzheimer's disease in the United States</title><author>Makin, Charles ; Neumann, Peter ; Peschin, Sue ; Goldman, Dana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-cd12f02989e45be6fc883cb397e0f03d138d4419f512b23b323177416d8afb0e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer's disease</topic><topic>Caregivers</topic><topic>Cost of Illness</topic><topic>cost-effectiveness analysis</topic><topic>drug therapy</topic><topic>Health Care Costs</topic><topic>healthcare costs</topic><topic>Humans</topic><topic>medical expenditure</topic><topic>quality-adjusted life year</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Makin, Charles</creatorcontrib><creatorcontrib>Neumann, Peter</creatorcontrib><creatorcontrib>Peschin, Sue</creatorcontrib><creatorcontrib>Goldman, Dana</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medical economics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Makin, Charles</au><au>Neumann, Peter</au><au>Peschin, Sue</au><au>Goldman, Dana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Modelling the value of innovative treatments for Alzheimer's disease in the United States</atitle><jtitle>Journal of medical economics</jtitle><addtitle>J Med Econ</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>24</volume><issue>1</issue><spage>764</spage><epage>769</epage><pages>764-769</pages><issn>1369-6998</issn><eissn>1941-837X</eissn><abstract>Alzheimer's disease (AD) is the predominant cause of dementia and a leading cause of death globally. With no cure or treatment to slow disease progression, AD-related healthcare costs are substantial and increase as the severity of the disease progresses. Given the complexity of this disease, including initial pathophysiological damage occurring decades before clinical manifestation, finding new impactful treatments for AD relies on highly innovative research and development. However, such sizable and sustained investments bring into question whether conventional value assessment models are fit for this purpose. In this article, we examine the importance and challenges of assimilating the perspectives of varied stakeholders, including patients, caregivers, health systems, payers, and society at large, into a comprehensive value assessment model that may be well suited for a breakthrough treatment for AD.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>33989095</pmid><doi>10.1080/13696998.2021.1927747</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1369-6998 |
| ispartof | Journal of medical economics, 2021-01, Vol.24 (1), p.764-769 |
| issn | 1369-6998 1941-837X |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_13696998_2021_1927747 |
| source | Taylor & Francis Open Access; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Alzheimer Disease - drug therapy Alzheimer's disease Caregivers Cost of Illness cost-effectiveness analysis drug therapy Health Care Costs healthcare costs Humans medical expenditure quality-adjusted life year United States |
| title | Modelling the value of innovative treatments for Alzheimer's disease in the United States |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T22%3A44%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Modelling%20the%20value%20of%20innovative%20treatments%20for%20Alzheimer's%20disease%20in%20the%20United%20States&rft.jtitle=Journal%20of%20medical%20economics&rft.au=Makin,%20Charles&rft.date=2021-01-01&rft.volume=24&rft.issue=1&rft.spage=764&rft.epage=769&rft.pages=764-769&rft.issn=1369-6998&rft.eissn=1941-837X&rft_id=info:doi/10.1080/13696998.2021.1927747&rft_dat=%3Cproquest_cross%3E2528175535%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2528175535&rft_id=info:pmid/33989095&rfr_iscdi=true |